Armis Advisers, LLC Gain Therapeutics, Inc. Transaction History
Armis Advisers, LLC
- $1.07 Trillion
- Q1 2025
A detailed history of Armis Advisers, LLC transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Armis Advisers, LLC holds 10,750 shares of GANX stock, worth $20,425. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,750Holding current value
$20,425% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding GANX
# of Institutions
37Shares Held
3.1MCall Options Held
8.4KPut Options Held
8.7K-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$1.12 Million0.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$1.08 Million0.05% of portfolio
-
Geode Capital Management, LLC Boston, MA282KShares$536,2000.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA255KShares$484,4810.0% of portfolio
-
Marshall Wace, LLP London, X0196KShares$372,4490.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $22.6M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...